MEI Pharma
MEI Pharma
MEIP
NASDAQ
3.10
USD
26.53%
About
MEI Pharma, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing novel and differentiated cancer therapies. Its drug candidate pipeline includes Voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and ME-344, an intravenous small molecule mitochondrial inhibitor targeting the oxidative phosphorylation pathway.
Voruciclib is a potent and selective orally administered CDK9 inhibitor. Voruciclib is being studied in a Phase 1 trial evaluating dose and schedule in patients with acute myeloid leukemia (AML) and B-cell malignancies as a single-agent, and in combination with the B-cell lymphoma 2 (BCL) inhibitor venetoclax (marketed as Venclexta) in patients with AML.
ME-344 is a novel mitochondrial inhibitor drug candidate that demonstrates tumor selective activity in pre-clinical studies. It targets the OXPHOS pathway involved in the production of adenosine triphosphate (ATP)..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 14.3K |
| Three Month Average Volume | 2.2M |
| High Low | |
| Fifty-Two Week High | 6.9099 USD |
| Fifty-Two Week Low | 2.7293 USD |
| Fifty-Two Week High Date | 07 Dec 2023 |
| Fifty-Two Week Low Date | 04 Jun 2024 |
| Price and Volume | |
| Current Price | 3.1 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -13.19% |
| Thirteen Week Relative Price Change | 1.27% |
| Twenty-Six Week Relative Price Change | -33.66% |
| Fifty-Two Week Relative Price Change | -40.13% |
| Year-to-Date Relative Price Change | -54.87% |
| Price Change | |
| One Day Price Change | -4.91% |
| Thirteen Week Price Change | 8.39% |
| Twenty-Six Week Price Change | -27.06% |
| Five Day Price Change | -1.27% |
| Fifty-Two Week Price Change | -24.98% |
| Year-to-Date Price Change | -46.55% |
| Month-to-Date Price Change | -16.44% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 3.69563 USD |
| Book Value Per Share (Most Recent Quarter) | 7.65856 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 3.69563 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 7.65856 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | 3.42158 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 7.32643 USD |
| Revenue Per Share (Trailing Twelve Months) | 10.01861 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -4.77833 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | 3.92541 USD |
| Normalized (Last Fiscal Year) | -4.77833 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -4.77833 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | 3.92541 USD |
| Including Extraordinary Items (Last Fiscal Year) | -4.77833 USD |
| Including Extraordinary Items (Trailing Twelve Months) | 3.92541 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 15.11226 USD |
| Cash Per Share (Most Recent Quarter) | 8.48747 USD |
| Cash Flow Per Share (Last Fiscal Year) | -4.7204 USD |
| Cash Flow Per Share (Trailing Twelve Months) | 3.97884 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -6.57106 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -83 |
| Cash Flow Revenue (Trailing Twelve Months) | -66 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | 39.18% |
| Pretax Margin (Last Fiscal Year) | -65.22% |
| Pretax Margin (5 Year) | -122.05% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -75.31% |
| Operating Margin (Trailing Twelve Months) | 33.62% |
| Operating Margin (5 Year) | -155.83% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -65.22% |
| Net Profit Margin (Trailing Twelve Months) | 39.18% |
| Net Profit Margin (5 Year) | -122.05% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -23.75% |
| Tangible Book Value (5 Year) | -13.26% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -100.00% |
| Revenue Growth (3 Year) | 97.56% |
| Revenue Change (Trailing Twelve Months) | 13.58% |
| Revenue Per Share Growth | 56.40% |
| Revenue Growth (5 Year) | 20.71% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 40.88% |
| EPS Change (Trailing Twelve Months) | 169.03% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 0 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -56,552,000 |
| Net Debt (Last Fiscal Year) | -100,693,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 0 |
| Price to Sales (Trailing Twelve Months) | 0 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | 1 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | 1 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 2 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 1 |
| PE Including Extraordinary Items (Trailing Twelve Months) | 1 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 0 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | 44.58% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -1 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 5 |
| Current Ratio (Most Recent Quarter) | 6 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -52,519,000 |
| Free Cash Flow (Trailing Twelve Months) | -43,783,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -21.32% |
| Return on Assets (Trailing Twelve Months) | 25.46% |
| Return on Assets (5 Year) | -25.31% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -82.66% |
| Return on Equity (Trailing Twelve Months) | 61.27% |
| Return on Equity (5 Year) | -72.46% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -25.08% |
| Return on Investment (Trailing Twelve Months) | 30.38% |
| Return on Investment (5 Year) | -28.59% |